Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.

Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO

Reproductive biomedicine online24 Apr 2017Cited by 109 (Europe PMC)

PMID28479118DOI10.1016/j.rbmo.2017.03.023PepBankPUB-28479118

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight women with PCOS, liraglutide caused 5.2 kg more weight loss than placebo.
In plain wordsIn overweight women with PCOS, liraglutide led to more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight loss
Study
n = 72
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
Weight loss versus placebo
5.2 kg
liraglutide
Source sentences
Summary
Liraglutide caused 5.2 kg (95% CI 3.0 to 7.5, P < 0.0001) weight loss compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911801
02HumanRandomized controlled trialEfficacy outcome
In women with PCOS, the bleeding ratio improved more with liraglutide than with placebo, with a between-group difference of 0.14.
In plain wordsIn women with PCOS, liraglutide improved the bleeding pattern more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseBleeding ratio
Study
n = 72
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Bleeding ratio improved with liraglutide: 0.28 (95% CI 0.20 to 0.36, P < 0.001); placebo: 0.14 (95% CI 0.02 to 0.26, P < 0.05); between-group difference: 0.14 (95% CI 0.03 to 0.24, P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911802
03HumanRandomized controlled trialEfficacy outcome
In women with PCOS, ovarian volume decreased by 1.6 ml with liraglutide versus placebo, but the 95% confidence interval included zero.
In plain wordsIn women with PCOS, ovarian volume fell slightly more with liraglutide than with placebo, but the difference was not clear.
Peptide
Liraglutide
Outcome
No significant changeOvarian volume
Study
n = 72
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Ovarian volume decreased by -1.6 ml (95% CI -3.3 to 0.1) with liraglutide versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911805
04HumanRandomized controlled trialSafety outcome
In women with PCOS, nausea was more prevalent in the liraglutide group than with placebo.
In plain wordsIn women with PCOS, nausea was more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n = 72
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Nausea and constipation were more prevalent in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911806
05HumanRandomized controlled trialSafety outcome
In women with PCOS, constipation was more prevalent in the liraglutide group than with placebo.
In plain wordsIn women with PCOS, constipation was more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseConstipation
Study
n = 72
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Nausea and constipation were more prevalent in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911807
06HumanRandomized controlled trialEfficacy outcome
In women with PCOS, SHBG increased by 7.4 nmol/L in the liraglutide group.
In plain wordsIn women with PCOS, liraglutide was followed by a rise in SHBG, a hormone-binding protein.
Peptide
Liraglutide
Outcome
IncreaseSHBG change
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
In the liraglutide group, SHBG increased by 7.4 nmol/L (95% CI 4.1 to 10.7)
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911803
07HumanRandomized controlled trialEfficacy outcome
In women with PCOS, free testosterone decreased by 0.005 nmol/L in the liraglutide group.
In plain wordsIn women with PCOS, free testosterone fell slightly in the liraglutide group.
Peptide
Liraglutide
Outcome
DecreaseFree testosterone change
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
free testosterone decreased by 0.005 nmol/L (95% CI -0.009 to -0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio.
Report a problemFND-2847911804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT05952882

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Mỹ Đức Hospitaln = 188est. 1 Nov 2023 to est. 31 Dec 2025

Polycystic Ovary Syndrome · Obesity · Infertility, Female

Trial page ClinicalTrials.govUpdated 23 Oct 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.